Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models. (October 2020)

Record Type:
Journal Article
Title:
Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models. (October 2020)
Main Title:
Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models
Authors:
Mcsheehy, P.
Boult, J.
Robinson, S.
Bachmann, F.
El Shemerly, M.
Kellenberger, L.
Lane, H.
Abstract:
Is Part Of:
European journal of cancer. Volume 138(2020)Supplement 2
Journal:
European journal of cancer
Issue:
Volume 138(2020)Supplement 2
Issue Display:
Volume 138, Issue 1 (2020)
Year:
2020
Volume:
138
Issue:
1
Issue Sort Value:
2020-0138-0001-0000
Page Start:
S25
Page End:
S26
Publication Date:
2020-10
Subjects:
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:
http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/S0959-8049(20)31133-3 ↗
Languages:
English
ISSNs:
0959-8049
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:
15525.xml